Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-08-13
DOI
10.3389/fimmu.2018.01668
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Paraoxonases and psoriasis: negative imbalance of antioxidant endogenous mechanisms
- (2019) Maria Schiattarella et al. GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA
- Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis
- (2018) A. Egeberg et al. BRITISH JOURNAL OF DERMATOLOGY
- Limitations of current monoclonal antibodies for plaque-type psoriasis and an outlook for the future
- (2018) Annunziata Raimondo et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Immune-Mediated Inflammation Promotes Subclinical Atherosclerosis in Recent-Onset Psoriatic Arthritis Patients without Conventional Cardiovascular Risk Factors
- (2018) Rodolfo A. Kolliker Frers et al. Frontiers in Immunology
- Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences
- (2018) Wolf-Henning Boehncke Frontiers in Immunology
- Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders
- (2017) Anna Balato et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Cardiovascular and Metabolic Diseases Comorbid with Psoriasis: Beyond the Skin
- (2017) Masutaka Furue et al. INTERNAL MEDICINE
- Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment
- (2017) Stephen Hu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-α inhibitors versus methotrexate
- (2017) Jashin J. Wu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data
- (2017) Bruce Strober et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of interleukin-17 antagonists in patients with plaque psoriasis: a meta-analysis from phase 3 randomized controlled trials
- (2017) D. Wu et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- TNFα and its Receptors in Psoriatic Skin, before and after Treatment with Etanercept
- (2017) G. Caldarola et al. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
- New insights into the role of T cells in pathogenesis of psoriasis and psoriatic arthritis
- (2016) Jacek Karczewski et al. AUTOIMMUNITY
- A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity
- (2016) Andrea Chiricozzi et al. Expert Review of Clinical Immunology
- Impact of adalimumab treatment on cardiovascular risk biomarkers in psoriasis: Results of a pilot study
- (2016) Spyridon Gkalpakiotis et al. JOURNAL OF DERMATOLOGY
- The effect of etanercept on vascular endothelial growth factor production by cutaneous mesenchymal stem cells from patients with psoriasis
- (2016) Anna Campanati et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- IL-36γ Is Involved in Psoriasis and Allergic Contact Dermatitis
- (2016) Anna Balato et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Evaluation of efficacy and safety of ABP 501 in a phase 3 study in subjects with moderate to severe plaque psoriasis: 52-week results
- (2016) JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
- (2016) Peter C.M. van de Kerkhof et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Subclinical cardiovascular disease and it's improvement after long-term TNF-α inhibitor therapy in severe psoriatic patients
- (2016) E. Herédi et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Association Between Psoriasis and Subclinical Atherosclerosis
- (2016) Na Fang et al. MEDICINE
- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
- (2016) Kenneth B. Gordon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association Between Changes in Coronary Artery Disease Progression and Treatment With Biologic Agents for Severe Psoriasis
- (2016) Kasper Fjellhaugen Hjuler et al. JAMA Dermatology
- Cytokines in psoriasis
- (2015) Jaymie Baliwag et al. CYTOKINE
- Psoriasis Is a Systemic Disease with Multiple Cardiovascular and Metabolic Comorbidities
- (2015) Caitriona Ryan et al. DERMATOLOGIC CLINICS
- Vitamin A Decreases Cytotoxicity of Oxidized Low-Density Lipoprotein in Patients with Atherosclerosis
- (2015) Mohammad Jafar Mahmoudi et al. IMMUNOLOGICAL INVESTIGATIONS
- Psoriasis and the Risk of Major Cardiovascular Events: Cohort Study Using the Clinical Practice Research Datalink
- (2015) Rosa Parisi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Myocardial function and effects of biologic therapy in patients with severe psoriasis: a prospective echocardiographic study
- (2015) O. Ahlehoff et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Anti-TNF-α therapy reduces retinol-binding protein 4 serum levels in non-diabetic patients with psoriasis: a 6-month prospective study
- (2015) T. Pina et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
- (2015) Christopher E M Griffiths et al. LANCET
- Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
- (2015) Hervé Bachelez et al. LANCET
- Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
- (2015) Mark Lebwohl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin 23 Levels Are Increased in Carotid Atherosclerosis
- (2015) Azhar Abbas et al. STROKE
- CCL20andIL22Messenger RNA Expression After Adalimumab vs Methotrexate Treatment of Psoriasis
- (2015) Ari M. Goldminz et al. JAMA Dermatology
- Atherosclerosis in psoriatic disease: latest evidence and clinical implications
- (2015) Lihi Eder et al. Therapeutic Advances in Musculoskeletal Disease
- Interleukin 17 Drives Vascular Inflammation, Endothelial Dysfunction, and Arterial Hypertension in Psoriasis-Like Skin Disease
- (2014) Susanne Karbach et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Point: Major adverse cardiovascular events and anti-IL 12/23 agents
- (2014) Thrasivoulos Tzellos et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Anti-TNF-α therapy improves insulin sensitivity in non-diabetic patients with psoriasis: a 6-month prospective study
- (2014) T. Pina et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Vitamin A Supplementation Reduces IL-17 and RORc Gene Expression in Atherosclerotic Patients
- (2014) A. Mottaghi et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- IL-17 in psoriasis: Implications for therapy and cardiovascular co-morbidities
- (2013) Jackelyn B. Golden et al. CYTOKINE
- Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study
- (2013) O. Ahlehoff et al. JOURNAL OF INTERNAL MEDICINE
- Incidence of Cardiovascular Disease in Individuals with Psoriasis: A Systematic Review and Meta-Analysis
- (2013) Eleanor J. Samarasekera et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Major cardiovascular events associated with anti-IL 12/23 agents: A tale of two meta-analyses
- (2013) Erica D. Dommasch et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Association of ethnicity, tumor necrosis factor inhibitor therapy, and myocardial infarction risk in patients with psoriasis
- (2013) Jashin J. Wu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Impact of effective tumor necrosis factor-alfa inhibitor treatment on arterial intima-media thickness in psoriasis: Results of a pilot study
- (2013) Hajnalka Jókai et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Effects of adalimumab therapy in adult subjects with moderate-to-severe psoriasis on Th17 pathway
- (2013) A. Balato et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis
- (2013) Nehal N Mehta et al. Journal of Translational Medicine
- Metabolic syndrome and skin: Psoriasis and beyond
- (2013) Tanmay Padhi et al. INDIAN JOURNAL OF DERMATOLOGY
- Interleukin-12 Is Associated With Arterial Stiffness in Healthy Individuals
- (2012) K. Yong et al. AMERICAN JOURNAL OF HYPERTENSION
- Association Between Tumor Necrosis Factor Inhibitor Therapy and Myocardial Infarction Risk in Patients With Psoriasis
- (2012) Jashin J. Wu et al. ARCHIVES OF DERMATOLOGY
- Effects of the Tumor Necrosis Factor-α Antagonist Adalimumab on Arterial Inflammation Assessed by Positron Emission Tomography in Patients With Psoriasis
- (2012) Robert Bissonnette et al. Circulation-Cardiovascular Imaging
- Cytokine-Based Therapy in Psoriasis
- (2012) Anupam Mitra et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction
- (2012) Tabassome Simon et al. EUROPEAN HEART JOURNAL
- Pathogenic Mechanisms Shared between Psoriasis and Cardiovascular Disease
- (2012) Ramin Ghazizadeh et al. International Journal of Medical Sciences
- Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study
- (2012) A.B. Kimball et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials
- (2012) T. Tzellos et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systematic Review and Meta-Analysis of Methotrexate Use and Risk of Cardiovascular Disease
- (2011) Renata Micha et al. AMERICAN JOURNAL OF CARDIOLOGY
- The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study
- (2011) K. Abuabara et al. BRITISH JOURNAL OF DERMATOLOGY
- Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies
- (2011) K. Reich et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
- (2011) B.E. Strober et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
- (2011) A.B. Gottlieb et al. BRITISH JOURNAL OF DERMATOLOGY
- Psoriasis and atherosclerosis: two plaques, one syndrome?
- (2011) A. J. Flammer et al. EUROPEAN HEART JOURNAL
- The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity
- (2011) Wolf-Henning Boehncke et al. EXPERIMENTAL DERMATOLOGY
- Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events
- (2011) Thrasivoulos Tzellos et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events
- (2011) Caitriona Ryan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association Between Disease-Modifying Antirheumatic Drugs and Diabetes Risk in Patients With Rheumatoid Arthritis and Psoriasis
- (2011) Daniel H. Solomon JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- TNF alpha antagonist therapy and safety monitoring
- (2011) Thao Pham et al. JOINT BONE SPINE
- A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis
- (2011) Kenneth B. Gordon et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study
- (2011) S. Boehncke et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- A 52-Week Trial Comparing Briakinumab with Methotrexate in Patients with Psoriasis
- (2011) Kristian Reich et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial
- (2010) Sandra Boehncke et al. ARCHIVES OF DERMATOLOGICAL RESEARCH
- Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability
- (2010) Christian Erbel et al. BASIC RESEARCH IN CARDIOLOGY
- Prognostic value of cytokines and chemokines in addition to the GRACE Score in non-ST-elevation acute coronary syndromes
- (2010) Luis C.L. Correia et al. CLINICA CHIMICA ACTA
- Positive treatment effects of ustekinumab in psoriasis: Analysis of lesional and systemic parameters
- (2010) Manjula REDDY et al. JOURNAL OF DERMATOLOGY
- Emerging Role of IL-17 in Atherosclerosis
- (2010) Shuang Chen et al. Journal of Innate Immunity
- Psoriasis Is Not a Useful Independent Risk Factor for Cardiovascular Disease
- (2010) Robert S. Stern JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions
- (2010) Batya B. Davidovici et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Interleukin-17 and Interferon-γ Are Produced Concomitantly by Human Coronary Artery–Infiltrating T Cells and Act Synergistically on Vascular Smooth Muscle Cells
- (2009) Raymond E. Eid et al. CIRCULATION
- Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis
- (2009) Soraya Taleb et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Psoriasis May Not be an Independent Risk Factor for Acute Ischemic Heart Disease Hospitalizations: Results of a Large Population-Based Dutch Cohort
- (2009) Marlies Wakkee et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Circulating Th17, Th22, and Th1 Cells Are Increased in Psoriasis
- (2009) Shinji Kagami et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Inflammation in Atherosclerosis
- (2009) Peter Libby et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial
- (2009) Alice Gottlieb et al. LANCET
- The Th17/Treg imbalance in patients with acute coronary syndrome
- (2008) Xiang Cheng et al. CLINICAL IMMUNOLOGY
- Chronic Plaque Psoriasis Is Associated with Increased Arterial Stiffness
- (2008) Paolo Gisondi et al. DERMATOLOGY
- A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease
- (2008) William J. Sandborn et al. GASTROENTEROLOGY
- Lymphoid tissue inducer–like cells are an innate source of IL-17 and IL-22
- (2008) Hiroaki Takatori et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category
- (2008) Dror Luger et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Anti–tumour necrosis factor-α therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study
- (2008) P Gisondi et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now